Syros Pharmaceuticals, Inc. - common stock (SYRS) News
Filter SYRS News Items
SYRS News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
SYRS News Highlights
- For SYRS, its 30 day story count is now at 8.
- Over the past 11 days, the trend for SYRS's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
- IBRX are the most mentioned tickers in articles about SYRS.
Latest SYRS News From Around the Web
Below are the latest news stories about SYROS PHARMACEUTICALS INC that investors may wish to consider to help them evaluate SYRS as an investment opportunity.
Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Q1 2023 Earnings Call TranscriptSyros Pharmaceuticals, Inc. (NASDAQ:SYRS) Q1 2023 Earnings Call Transcript May 10, 2023 Syros Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is $-0.85, expectations were $-1.09. Operator: Good morning, and welcome to Syros Pharmaceuticals’ First Quarter 2023 Financial Results Conference Call. [Operator Instructions]. This call is being webcast live on the Investors and Media section of […] |
Q1 2023 Syros Pharmaceuticals Inc Earnings CallQ1 2023 Syros Pharmaceuticals Inc Earnings Call |
Syros Pharmaceuticals, Inc. (SYRS) Reports Q1 Loss, Tops Revenue EstimatesSyros Pharmaceuticals, Inc. (SYRS) delivered earnings and revenue surprises of 24.11% and 0.14%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock? |
Syros Reports First Quarter 2023 Financial Results and Provides a Corporate UpdateCAMBRIDGE, Mass., May 10, 2023--Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today reported financial results for the quarter ended March 31, 2023 and provided a corporate update. |
Syros to Present at JMP Securities 2023 Life Sciences ConferenceCAMBRIDGE, Mass., May 09, 2023--Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced that its Chief Executive Officer, Nancy Simonian, M.D., will participate in a fireside chat at the JMP Securities 2023 Life Sciences Conference. Management will also be available for one-on-one meetings. Details are as follows: |
ImmunityBio (IBRX) Stock Jumps 43.2%: Will It Continue to Soar?ImmunityBio (IBRX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term. |
Syros to Report First Quarter 2023 Financial Results on Wednesday, May 10, 2023CAMBRIDGE, Mass., May 03, 2023--Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced that it will host a live conference call and webcast at 8:30 a.m. ET on Wednesday, May 10, 2023 to report its first quarter 2023 financial results and provide a corporate update. |
Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)CAMBRIDGE, Mass., May 02, 2023--Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced the grant of restricted stock unit (RSU) awards for an aggregate of 17,800 shares of Syros common stock to two newly hired employees in connection with commencing employment with Syros. These RSUs were granted as a material inducement to employment in accordance with Nasdaq Listing Ru |
Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Q4 2022 Earnings Call TranscriptSyros Pharmaceuticals, Inc. (NASDAQ:SYRS) Q4 2022 Earnings Call Transcript March 2, 2023 Operator: Good morning, and welcome to Syros Pharmaceuticals Fourth Quarter and Full Year 2022 Financial Results Conference Call. At this time, all participants are in a listen-only mode. This call is being webcast live on the Investors and Media section of Syros’ website […] |
Syros Pharmaceuticals Full Year 2022 Earnings: EPS Beats Expectations, Revenues LagSyros Pharmaceuticals ( NASDAQ:SYRS ) Full Year 2022 Results Key Financial Results Revenue: US$14.9m (down 37% from FY... |